1 / 119

Treatment of Major Rheumatic Diseases

Treatment of Major Rheumatic Diseases. Dr Tanya Potter Consultant Rheumatologist. Aims. 1 To pass your exam 2 Encourage safe prescribing (and you will remember that have an exam in this also). Rheumatoid arthritis (RA) or osteoarthritis (OA) most common types seen in clinics (& exams)

betsy
Télécharger la présentation

Treatment of Major Rheumatic Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Treatment of Major Rheumatic Diseases Dr Tanya Potter Consultant Rheumatologist

  2. Aims • 1 To pass your exam • 2 Encourage safe prescribing (and you will remember that have an exam in this also)

  3. Rheumatoid arthritis (RA) or osteoarthritis (OA) most common types seen in clinics (& exams) • Dramatically improved treatments in past 20 yrs

  4. Osteoarthritis • most common • 75% people > 70 radiographic OA F: M 2.5:1

  5. Osteoarthritis • Joint space narrowing • Osteophytes • Subchondral sclerosis • Bone cysts

  6. Management • Pain relief is key • Seek improvement in joint mobility or walking time • e.g. how long it takes for pt to walk to end of corridor • Quality of life- can use functional measures to see how well person is doing. Use several simple questions: • How well can one button clothes? • Can make own meals everyday? • Gives good reliable data

  7. OA - Goals of Treatment • No cure • Meds can improve function by reducing pain • Can limit final impairment • Non-pharmacological and pharmacological Non-pharmacological • Patient education (education leaflets/ websites) • Wt loss (10-15 lb weight loss can reduce pain 100%) • Every lb gained, X four across weight bearing joint • Muscle strengthening important -esp. quads muscle • PT & OT important • Use devices for joint protection (canes, walkers etc…)

  8. Drugs • Mild to moderate • Paracetamol; • Topical agents: non steroidals, rubefacients • Moderate to severe • As above, plus • NSAIDs • combination analgesics (paracet +opiods) / Opiods/ Tramadol

  9. Paracetamol • Analgesic/ antipyretic • Unknown mechanism of action • combo with opiods better response when can’t use NSAIDs (gu / du/ renal/ warfarin) • Doesn’t alter platelet function (bleeding/ surgery) • Safer for elderly • Caution with chronic liver dz (hepatotoxicity, > 2 gm) • Thrombocytopaenia, neutropaenia rare

  10. Tramadol • Centrally acting analgesic • Use in addition to NSAID • Effects mu receptors; Same potency as opiods • Can use as adjunctive therapy • Less opiod SE; esp constipation/ nausea/ vomiting • Balance problems • smaller potential of abuse or dose acceleration, (pt needs more drug in shorter time period) c.f. opiods

  11. Strong opiods • Use in pt with limited options • loss of function due to pain • renal or heart disease preventing operation • Select pt carefully • Use during period of disease flare, then decrease use • Limitations • Nausea, vomiting, constipation, ***urinary retention • Chronic use leads to physical dependence • Can use with anti-inflammatory • Lots of choice (short or long acting, patches)

  12. NSAIDS • 25 million NSAID prescriptions/ yr in UK • Non selective • Aspirin • Ibuprofen • Naproxen • Indomethacin • Piroxicam • Selective cox 2 inhibiters • Celecoxib • Etoricoxib • Meloxicam • etodolac

  13. NSAID risk • How many GI bleed admissions annually in the uk? • What percentage are likely to due to NSAIDs? • How many deaths annually?

  14. Upper GI complications • 65,000 emergency upper GI admissions p.a. in UK • 12,000 of these admissions (including 2,230 deaths) attributable to NSAID use • Further 330 attributable deaths occur in community • ~2% of NSAID users admitted annually for GI emergencies

  15. GI event may be devoid of warning symptoms Many patients asymptomatic prior to serious NSAID-associated GI event (bleeding, perforation) n = 141 n = 1,921 19% 58% 42% 81% without symptoms with symptoms

  16. prostoglandins

  17. NSAIDs: Inhibit cox enzymes Asthma blocked

  18. Action • Reduce prostaglandin production- less inflammatory mediators • Unopposed leukotrione action • Antipyretic effects – partly due to a decrease in prostaglandin that is responsible for elevating the hypothalamic set point for temp control in fever

  19. COX enzyme • Cyclo-oxygenase (COX) has two forms • COX-1 : protects the stomach lining from harsh acids and digestive chemicals. It also helps maintain kidney function • COX-2 : is produced when joints are inflamed or injured

  20. Action • Different NSAID’s inhibit the enzyme by different mechanisms • Aspirin – binds covalently with a serine residue of the enzyme (irreversible) • Ibuprofen/Piroxicam – reversible competitive inhibitors of COX non selective • Paracetamol – acts partly by reducing cytoplasmic peroxidase

  21. Older nonselective NSAID’s (Ibuprofen, Naproxen) • Block both COX-1 and COX-2, GI upset, bleeding as well as decreasing inflammation • Advice patients to take them with food or a glass of milk and should avoid alcohol. • Pros: • OTC version of these drugs are inexpensive • Low doses of aspirin taken over long term helps to prevent heart attacks, strokes and bowel cancer • Cons: • GI upset ie nausea, ulcers • Kidney problems from overuse • Interacts with warfarin

  22. COX-2 inhibitors (Celecoxib, meloxicam, etorocoxib) • Target only the COX-2 enzyme that stimulates the inflammatory response • Pros : • less likely to cause GI upset compared to the older NSAID’s • longer lasting drug – longer relief • do not thin the blood therefore can consider co-prescription with warfarin • Cons: • More expensive compared to traditional NSAID’s • Results not as good as endoscopic drug studies suggest

  23. Indications • Commonest use – arthritis ie RA or OA and gout • Back pain, sciatica, sprains and strains and rheumatism • Dental pain • Post op pain • Period pain • Renal/ureteric colic • Fever • migraines

  24. CAUTIONS • Elderly • Pregnancy- miscarriage, early closure of ductus arteriosus • Breast feeding • Coagulation defects • Renal, cardiac (heart failure/ hypertension/ IHD) or hepatic impairment

  25. Contraindications • Severe heart failure • COX-2 : IHD, stroke, PVD and moderate to severe heart failure • CSM advice – previous or active peptic ulceration • hypersensitivity to aspirin or any NSAID – which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated.

  26. SIDE EFFECTS • GI – N&D, dyspepsia bleeding and ulceration, • Hypersensitivity • Headaches, dizziness, nervousness, depression, drowsiness, insomnia, hearing disturbances • Photosensitivity • Fluid retention (heart failure), raise blood pressure • Hepatic damage, pancreatitis • Eye and lung changes (alveolitis) • Stevens-Johnson syndrome & toxic epidermal necrolysis (rare)

  27. GI • Similar anti inflammatory effects of selective and non selective NSAIDs • Non selective: • 15-40% dyspepsia, nausea, abdo pain • 10% discontinue • Severe GI toxicity 4.5/100pt years • Selective Cox 2 inhibiters • Similar GI symptoms • < 6% discontinue • Severe toxicity 2.1/100 pt years NNT 42 to prevent 1 serious GI event

  28. Cardiovascular toxicity • Increased cardiovascular risk of selective NSAIDs is a problem • unopposed pro-thrombotic effects of COX-1-mediated production of thromboxane A2 • Also, coxibs effects on blood pressure and renal function could turn out to be more detrimental than those of conventional NSAIDs.

  29. prostoglandins

  30. CV risk • It is a real risk ‘APPROVE’ study • Data obscured by clinical trials not recruiting ‘normal pts’ • Data obscured by drug company manipulation of the results of clinical trials • Up to 42% higher risk of MI with selective • 0.6%/yr vs 0.3%/yr

  31. All NSAID/ CVS • Rise in BP 3-5mm • Equate with an increase • CCF 10-20% • CVA 20% • Angina 12% Lowest risk of all with naproxen (aspirin like effects)

  32. Naproxen • Pain and inflammation in rheumatic disorders • 0.5-1g / day in 1-3 divided doses • In high risk pts, give with PPI • Which one?

  33. NSAIDs - past strategies • Enteric Coating • Pro-drugs; hepatic metabolism • Gastro-protective agents:PPIs, misoprostol, H2 blockade

  34. OA- Adjunctive therapy • Intra articular steroids plus local anesthetic for joint inflammation • Decrease production of inflammatory mediators • Can last a 3-6 months; use with physio • Probably can be done safely up to four times a year • not too frequently; can effect the cartilage

  35. Visco-supplementation • Crosslinked hyaluronic acid polymers • OA (knee) • Intra-articular injections X 3-5 • Change viscosity in joint • Pain relief with improved mobility • Success rate is 50-70% for up to 4-6 months • no systemic SE

  36. Visco-supplementation • OA, where physio, weight loss, simple analgesia +/- NSAIDs insufficient • & IA steroids not helpful /not lasting • Awaiting/ unfit for surgery

  37. Capcaisin cream • 0.025% preparation (Zacin) • Depletes Substance P from nerve endings • Slow to act (1/12 to max effect) • More effective than topical NSAIDs • May reduce analgesic requirement

  38. What are the alternatives? • Cod liver oil & other fishy oils • Evening primrose oil • Borage or Starflower oil • Change in balance of cell membrane fatty acids

  39. Alternatives? • Glucosamine 1.5 gram/day • substrate for glucosaminoglycans • Pain relief & mobility • Possible 10-25% analgesic effect • -disease modifier ? • ? Nutrition for cartilage • ? Stimulate metabolism • Vitamin C • Framingham study results show reduced pain OA of knee & hip • may improve integrity of cartilage

  40. Gout • Joint inflammation caused by uric acid crystal deposits in the joint space

  41. Gout • Primary • Over production (10%) • Under secretion (90%) • Enzyme mutations • Predominantly secondary • Overproduction (mutations, heavy exercise, obesity) • Under excretion severe renal diseases, drugs, alcohol, HBP

  42. 2-17% of population are hyperuricaemic • The higher the uric acid the higher the chance of gout • Self reported adult prevalence of 8/1000 • 2-7M:1F • Increase in blacks may reflect increased rates of hypertension

  43. Figure 4 Simplified diagram of uric acid production and excretion 1/3 2/3 2/3 1/3 Roddy E et al. (2007) The changing epidemiology of gout Nat Clin Pract Rheumatol3: 443–449 doi:10.1038/ncprheum0556

  44. Epidemiology • Middle aged men • Dietary purine consumption • Alcohol • Drugs:Low dose aspirin, diuretics • Inherited metabolic abnormalities

  45. Clinical features • Gouty Tophi on pinnae • Olecranon bursitis • Gouty tophi on hands • Gouty nephropathy& stones • Large joint oligoarthritis • 1st metatarsophalangeal joint arthritis‘podagra’

  46. erosions with a punched out appearance

More Related